A Phase 1 study to evaluate the metabolism of [14C]PF-07104091 in healthy adult male participants
C4161006
Phase 1 other active
Quick answer
A Phase 1 study to evaluate the metabolism of [14C]PF-07104091 in healthy adult male participants for (HR) -positive human epidermal growth factor receptor 2 (HER2) -negative breast cancer (BC), non-small cell lung cancer (NSCLC), ovarian cancer, and triple negative breast cancer (TNBC) is a Phase 1 program (other) at Pfizer Ireland Pharmaceuticals Unlimited Company with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Pfizer Ireland Pharmaceuticals Unlimited Company
- Indication
- (HR) -positive human epidermal growth factor receptor 2 (HER2) -negative breast cancer (BC), non-small cell lung cancer (NSCLC), ovarian cancer, and triple negative breast cancer (TNBC)
- Phase
- Phase 1
- Modality
- other
- Status
- active